Strong Top-Line Growth
Revenue of CHF 2.6 billion in FY2025, representing organic revenue growth of 8.9% and reported growth of 4.1% (translation impact ~CHF 100 million).
Improved Profitability and Margins
Core EBIT margin of 26.5% at constant 2024 exchange rates (25.2% including currency effects). Core gross profit margin of 70.1% and core net result of CHF 478 million (net margin 18.3%).
Strong Cash Generation Despite High Investment
Free cash flow of CHF 290 million (11.1% of net revenue) in a year with elevated CapEx (CHF 223 million, +CHF 56 million vs prior year), demonstrating cash conversion while completing a large manufacturing investment cycle.
Record Product Launches and Rapid Commercial Adoption
iEXCEL implant: >1 million units sold (most successful implant launch in company history). SIRIOS X3 intraoral scanner launched Oct 2025 with strong momentum. Straumann AXS reached >15,000 active users within 18 months.
Regional Outperformance
EMEA organic growth above 11% for the full year (notable Q4 strength). North America showed sequential improvement with Q4 organic growth of 6.8%. Latin America delivered high double-digit organic growth around 18% and contributed 17% of group's total organic growth.
Orthodontics Transformation Progress
ClearCorrect manufacturing transition to Smartee progressing as planned for EMEA and APAC, expected to lower COGS and drive margin improvements from mid-2026 onward; new product features (scalloped trimline, mandibular repositioning) planned in 2026.
Sustainability and Education Impact
Trained >370,000 dental professionals (10,700 education programs); Scope 1 and 2 CO2 emissions reduced ~17% vs 2021; 98.5% of electricity consumption from renewable sources.
Capital Allocation and Shareholder Return
Proposed dividend of CHF 1.00 per share (+5% vs prior year), core payout ratio ~33%, reflecting strong cash generation and balanced capital allocation.